MX2023001137A - Beta-glucocerebrosidasa mutada con estabilidad mejorada. - Google Patents

Beta-glucocerebrosidasa mutada con estabilidad mejorada.

Info

Publication number
MX2023001137A
MX2023001137A MX2023001137A MX2023001137A MX2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A
Authority
MX
Mexico
Prior art keywords
glucocerebrosidase
polynucleotide
modified
gcase
polypeptide
Prior art date
Application number
MX2023001137A
Other languages
English (en)
Spanish (es)
Inventor
Amit Nathwani
Jenny Mcintosh
Romuald Corbau
Azadeh Kia
Carlos Miranda
Fabrizio Comper
Original Assignee
Freeline Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2011813.9A external-priority patent/GB202011813D0/en
Priority claimed from GBGB2100648.1A external-priority patent/GB202100648D0/en
Priority claimed from GBGB2105924.1A external-priority patent/GB202105924D0/en
Application filed by Freeline Therapeutics Ltd filed Critical Freeline Therapeutics Ltd
Publication of MX2023001137A publication Critical patent/MX2023001137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Neurology (AREA)
MX2023001137A 2020-07-29 2021-07-29 Beta-glucocerebrosidasa mutada con estabilidad mejorada. MX2023001137A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2011813.9A GB202011813D0 (en) 2020-07-29 2020-07-29 Polypeptide
GBGB2100648.1A GB202100648D0 (en) 2021-01-18 2021-01-18 Polypeptide
GBGB2105924.1A GB202105924D0 (en) 2021-04-26 2021-04-26 Polypeptide
PCT/GB2021/051969 WO2022023761A2 (en) 2020-07-29 2021-07-29 Polypeptide

Publications (1)

Publication Number Publication Date
MX2023001137A true MX2023001137A (es) 2023-02-22

Family

ID=77265101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001137A MX2023001137A (es) 2020-07-29 2021-07-29 Beta-glucocerebrosidasa mutada con estabilidad mejorada.

Country Status (16)

Country Link
US (1) US20240261433A1 (enExample)
EP (2) EP4643868A3 (enExample)
JP (1) JP7895925B2 (enExample)
KR (1) KR20230042513A (enExample)
CN (1) CN116322744A (enExample)
AU (2) AU2021316875B2 (enExample)
BR (1) BR112023001583A2 (enExample)
CA (1) CA3189801A1 (enExample)
DK (1) DK4118200T3 (enExample)
ES (1) ES3057448T3 (enExample)
FI (1) FI4118200T3 (enExample)
HR (1) HRP20251591T1 (enExample)
IL (1) IL299811A (enExample)
MX (1) MX2023001137A (enExample)
PT (1) PT4118200T (enExample)
WO (1) WO2022023761A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024394235A1 (en) 2023-12-08 2026-06-11 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
CN118086341B (zh) * 2024-04-25 2024-08-02 上海凌医生物科技有限公司 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框
TW202617982A (zh) 2024-06-24 2026-05-01 美商戴納立製藥公司 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036603A2 (en) * 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
IL150314A0 (en) * 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
CN104383556B (zh) 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
US8962564B2 (en) * 2010-11-08 2015-02-24 Amicus Therapeutics, Inc. Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9574184B2 (en) * 2013-09-25 2017-02-21 Children's Hospital Medical Center Lysosomal protein targeting sequence and therapeutic applications of same
PE20181922A1 (es) * 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
CN111542549A (zh) 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
AU2019300431A1 (en) 2018-07-13 2021-01-14 Ucl Business Ltd Glucocerebrosidase gene therapy
WO2020157248A1 (en) * 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides

Also Published As

Publication number Publication date
IL299811A (en) 2023-03-01
KR20230042513A (ko) 2023-03-28
EP4118200B1 (en) 2025-10-08
WO2022023761A2 (en) 2022-02-03
AU2026205139A1 (en) 2026-07-16
DK4118200T3 (da) 2025-12-08
AU2021316875A1 (en) 2023-02-23
US20240261433A1 (en) 2024-08-08
EP4118200A2 (en) 2023-01-18
JP7895925B2 (ja) 2026-07-28
CA3189801A1 (en) 2022-02-03
EP4643868A3 (en) 2026-04-08
WO2022023761A3 (en) 2022-03-10
AU2021316875B2 (en) 2026-04-02
FI4118200T3 (fi) 2025-12-12
ES3057448T3 (en) 2026-03-02
EP4643868A2 (en) 2025-11-05
JP2023535808A (ja) 2023-08-21
CN116322744A (zh) 2023-06-23
PT4118200T (pt) 2026-01-08
HRP20251591T1 (hr) 2026-01-30
BR112023001583A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
EP4643868A3 (en) Mutated beta-glucocerebrosidase with improved stability
CO2021008538A2 (es) Composiciones para la reducción de la expresión transgénica específica de drg
AR112057A1 (es) Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
MX2024015050A (es) L-asparaginasa modificada
PE20231949A1 (es) VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
MX2021009305A (es) Polinucleotidos.
AR095598A1 (es) Composiciones y métodos para construcciones quiméricas del virus del dengue en vacunas
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
AR115152A1 (es) Elementos reguladores de plantas y métodos de uso de los mismos
RU2017142006A (ru) Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
CL2020001428A1 (es) Terapia genética para la mucopolisacaridosis iiib.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MX2020005663A (es) Terapia genica para mucopolisacaridosis iii a.
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
CO2017005830A2 (es) Composiciones de vacuna para el virus del dengue
AR118005A1 (es) Administración del virus adenoasociado de polinucleótido de cln3
ECSP23095204A (es) Composiciones y métodos para mejorar la función visual
MX2022000038A (es) Virus del dengue atenuados.
AR126396A1 (es) VARIANTES DESOPTIMIZADAS DE SARS-CoV-2 Y MÉTODOS Y USOS DE LAS MISMAS